Trial Profile

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 28 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
Indications Advanced breast cancer; Anal cancer; Bladder cancer; Cervical cancer; Cholangiocarcinoma; Colon cancer; Gastric cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Merkel cell carcinoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Rectal cancer; Renal cancer; Solid tumours; Squamous cell cancer; Uterine cancer
Focus Therapeutic Use

Most Recent Events

25 Mar 2025 Planned End Date changed from 1 Oct 2028 to 30 Nov 2031.
25 Mar 2025 Planned primary completion date changed from 1 Oct 2028 to 30 Nov 2030.
19 Mar 2024 Planned End Date changed from 1 Oct 2026 to 1 Oct 2028.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com